Phase 2 Heart Disease Trial, Recruiting NCT07372040 Sponsor: Tanta University Condition: Heart Disease
Back to Heart Disease

Phase 2 Heart Disease Trial, Recruiting

NCT07372040
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older (male or female)
  • People who have been admitted to hospital with a diagnosis of acute worsening heart failure, with at least one sign of fluid buildup in the body — such as swelling (edema), fluid in the abdomen (ascites confirmed by ultrasound), or fluid around the lungs (confirmed by chest X-ray or ultrasound)

Who may not be able to join:

  • People with Type 1 diabetes
  • People with significant kidney disease where the kidneys are functioning at a reduced level (eGFR below 30 mL/min per 1.73 m²), or people who require ongoing dialysis
  • People with a systolic (top number) blood pressure reading below 90 mmHg
  • People in cardiogenic shock (when the heart is suddenly unable to pump enough blood to meet the body's needs)
  • People already taking a medication called acetazolamide on a regular basis
  • People who have taken certain medications — specifically an SGLT2 inhibitor, a thiazide, or a thiazide-like water tablet — within the 48 hours before being enrolled in the trial
  • People whose heart failure has been triggered by a condition requiring urgent treatment, such as a heart attack, dangerous irregular heart rhythms, or a blood clot in the lungs
  • People who are pregnant or breastfeeding
  • People with moderate to severe anaemia (low red blood cell levels)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dalia A Gomaa, MSc in clinical pharmacy, Tanta University

Phone: +20+01063410525

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
1 February 2026
Est. completion
1 February 2027

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The cumulative urine output measured over 3 days

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov